Victims who developed breast cancer are facing heavy physical and financial burdens as they adjust their lives to their diagnosis. Despite these challenges, victims should know that they might be entitled to fair legal compensation for their cancer caused by EtO exposure.
A 2023 research paper found that people living within two miles of an EtO-emitting facility have a 60% increased risk of developing ductal carcinoma in situ (DCIS), one of the most common types of breast cancer. Furthermore, several other studies have come to the same conclusion, which strengthens the connection between ethylene oxide exposure and the development of breast cancer.
In addition to DCIS, listed below are the other typical types of breast cancer:
- Inflammatory breast cancer
- Invasive lobular carcinoma
- Lobular carcinoma in situ (LCIS)
- Male breast cancer
- Paget's disease of the breast
- Recurrent breast cancer
- Triple-negative breast cancer (TNBC)
- Ductal carcinoma in situ (DCIS)
The IARC, EPA, CDC, and other government bodies have included ethylene oxide in the list of Group 1 human carcinogens.
How ethylene oxide causes breast cancer
Ethylene oxide functions as a direct-acting alkylating agent that chemically binds to DNA without metabolic activation. When inhaled, the gas gets into the bloodstream and disperses through the body, reaching breast tissue where it can harm DNA in mammary epithelial cells. EtO forms DNA adducts, particularly N7-(2-hydroxyethyl)guanine, which interfere with how DNA normally replicates. These adducts lead cells to make copying errors during replication, introducing mutations into the genetic code.
The genotoxic damage extends beyond simple mutations. EtO exposure induces several types of genetic damage:
- Chromosomal aberrations that mess up normal gene organization
- DNA strand breaks that fragment genetic material
- Mutations accumulating in cells throughout the body
According to assessments by the International Agency for Research on Cancer and the EPA, EtO causes cancer through this genotoxic mechanism. DNA damage starts a series of genetic and chromosomal changes that pile up over time and can lead to cancer.
Laboratory evidence shows that breast epithelial cells are vulnerable to damage from EtO. In vitro tests found DNA damage in cultured breast epithelial cells, increased with EtO dose, supporting a biological mechanism that could contribute to cancer development. This mechanistic evidence indicates breast tissue isn't immune to EtO's genotoxic effects, and the same DNA-damaging process causing other cancers operates in breast cells.
Government toxicology assessments acknowledge evidence for an association between EtO and breast cancer in human studies. They emphasize the genotoxic mode of action as key to cancer risk across multiple tissues, including breast tissue. The mechanistic foundation shows:
- EtO causes DNA damage via direct alkylation
- This produces adducts, mutations, and chromosomal aberrations
- These genetic changes can start carcinogenesis in breast tissue
The biological plausibility is supported by laboratory findings showing breast epithelial cells experience DNA damage after EtO exposure. Epidemiological signals from workplace studies show positive exposure-response trends for breast cancer risk, and environmental studies indicate increased risk for early-stage breast lesions near EtO emissions.
Breast cancer diagnosed before age 50
Early-onset breast cancer, diagnosed before age 50, accounts for a significant share of cases without any identifiable hereditary cause. These cases tend to be more aggressive, progress faster, and are harder to treat than those diagnosed later in life. When a younger patient tests negative for BRCA1, BRCA2, and other hereditary markers, oncologists and researchers increasingly look toward environmental and occupational exposures as contributing factors. Ethylene oxide is among the substances under study, given its established ability to damage DNA in cells throughout the body, including breast tissue.
Ethylene oxide and triple-negative breast cancer
Triple-negative breast cancer (TNBC) is a subtype that tests negative for estrogen receptors, progesterone receptors, and HER2 protein. TNBC is generally harder to treat and carries a higher risk of recurrence than other subtypes because it doesn’t respond to hormone therapies or HER2-targeted treatments.
Many patients diagnosed with TNBC are seeking answers, especially when there is no family history or identifiable genetic mutation to guide them. Researchers are still studying whether environmental carcinogens like EtO may contribute to TNBC development. EtO directly alkylates DNA in ways that affect cell replication broadly, and its effect on breast epithelial cells has been shown in lab settings.
Breast cancer after living near ethylene oxide emissions
Living near an EtO-emitting facility for an extended period carries measurable health risks. The EPA specifically notes that the greatest cancer risk is associated with long-term exposure, with lifetime residence near emitting facilities representing the highest cumulative risk category. Decades of low-level inhalation can produce the same DNA-damaging effects as occupational exposure, particularly for those who moved into affected communities during childhood.
Exposure that begins early in life and continues through adulthood represents one of the more concerning patterns researchers track, as the cumulative dose accumulates over a longer window and affects tissue during periods of development. Those who lived near emissions for 10 or more years, were exposed as children, or were diagnosed before age 50 with no family history, may have grounds for a claim.
What if I have no family history of breast cancer?
Many patients who develop breast cancer have no family history of the disease and do not test positive for known hereditary gene mutations. A negative genetic test does not mean that the cancer is not the result of environmental factors. It simply means the diagnosis cannot be attributed to an inherited gene variant. Environmental and occupational exposures are among the factors researchers and oncologists consider when a diagnosis has no clear hereditary explanation.
Ethylene oxide is a recognized environmental risk factor for breast cancer. Patients who are otherwise healthy, have no first-degree relatives with breast cancer, and have received a negative result on genetic panels such as BRCA testing may find that their oncologist points toward environmental exposure as a possible contributing cause. If you fall into this category and lived or worked near EtO-emitting facilities, your diagnosis may be connected to that exposure, and you may be entitled to compensation.